慢性肾病患者心血管病一级预防:该不该用阿司匹林?
慢性肾脏病患者心血管事件风险较高,但阿司匹林用于一级预防的作用尚不明确。Wolfe 等对 ASPREE 试验进行亚组分析,提示阿司匹林未减少心血管事件,而出血事件翻倍。因此不推荐阿司匹林用于慢性肾脏病一级预防,但需继续开展如 ATTACK 试验等研究。
要点
- ASPREE 亚组分析显示慢性肾病患者用阿司匹林未减少心血管事件。
- 同一分析中出血事件翻倍,支持不推荐用于一级预防。
- 需等待 ATTACK 等正在进行的试验进一步明确获益风险。
核心结论
- 慢性肾脏病患者中阿司匹林用于心血管疾病一级预防不能推荐,因未减少心血管事件且出血事件翻倍。
研究设计与样本
- 对 ASPirin in Reducing Events in the Elderly(ASPREE)试验进行的亚组分析。
主要发现
- 亚组分析提示阿司匹林未减少心血管事件,但出血事件翻倍。
临床怎么用
- 慢性肾脏病患者不应常规使用阿司匹林进行心血管疾病一级预防。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Despite the higher risk of cardiovascular events in patients with chronic kidney disease, the role of aspirin for primary prevention is unclear. In the current issue, Wolfe et al. present a subgroup analysis of the ASPirin in Reducing Events in the Elderly (ASPREE) trial that suggests there was no reduction in cardiovascular events but bleeding events were doubled. Aspirin cannot be recommended for primary prevention in chronic kidney disease, but the continuation of ongoing research, such as the Aspirin To Target Arterial Events in Chronic Kidney Disease (ATTACK trial), is warranted.
引用
- Major RW, Burton JO. "To take or not to take an aspirin?" The age-old question of cardiovascular disease primary prevention for people with chronic kidney disease. Kidney Int. 2021. PMID: 33509351. doi:10.1016/j.kint.2020.09.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。